Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments

doi:10.3748/wjg.v20.i20.6262

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 20

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16701)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-9) series.

Item

Count

PDF

1432

WORD

423

HTML

11993

Figures (1-2)

365

Tables (1-9)

248

Sum=14461

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1167

Download

1073

Sum=2240

May 28, 2014 (publication date) through Feb 3, 2025

Times Cited of This Article

Times Cited (109)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. May 28, 2014; 20(20): 6262-6278
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6262

Table 3 National Institute for Health and Care Excellence treatment guidelines

Guidelines	HBeAg positive	HBeAg negative	Decompensated
1^st line	48-wk of PEG-IFN-α-2a	48-wk of PEG-IFN-α-2a	ETV or TDF (LAM resistance)
2^nd line	TDF or ETV (TDF contraindication)	ETV or TDF
3^rd line	LAM + TDFor ETV + TDF (LAM resistance)	ETV or TDF

In adults with compensated liver disease, current guidelines advise first-line treatment with 48 wk of PEG-IFN-α-2a. If PEG-IFN-α-2a is contraindicated, tenofovir or entecavir should be trialed. PEG-IFN: Pegylated interferon; HBeAg: Hepatitis B e antigen; ETV: Entecavir; LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate.

Citation: Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278
URL: https://www.wjgnet.com/1007-9327/full/v20/i20/6262.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i20.6262